<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cervical cytology: Evaluation of atypical and malignant glandular cells</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cervical cytology: Evaluation of atypical and malignant glandular cells</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cervical cytology: Evaluation of atypical and malignant glandular cells</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Annekathryn Goodman, MD, MPH, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Warner K Huh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark H Einstein, MD, MS, FACS, FACOG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 18, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atypical glandular cells (AGC) on cervical cytology usually originate from the glandular epithelium of the endocervix or endometrium. They are a less common finding than abnormal squamous cells.</p><p>Patients with AGC require further evaluation for premalignant conditions of the cervix, uterus, and, rarely, ovary and fallopian tube. The evaluation of patients with cervical cytology demonstrating atypical and malignant glandular cells is reviewed here. Cervical cancer screening strategies and techniques, interpretation of cervical cytology results, follow-up of other abnormal cytology results, and management of cervical neoplasia are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3219.html" rel="external">"Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3205.html" rel="external">"Cervical cancer screening: The cytology and human papillomavirus report"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a>.)</p><p></p><p class="headingAnchor" id="H29161205"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Terminology for reporting cervical cytology was standardized by the Bethesda System in 1988 [<a href="#rid1">1</a>]. This system has been revised several times  (<a class="graphic graphic_table graphicRef102346" href="/z/d/graphic/102346.html" rel="external">table 1</a>) [<a href="#rid2">2-4</a>]. The terminology used to classify AGC is:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical glandular cells (AGC)</strong> – Either endocervical (AEC), endometrial, or not otherwise specified (NOS) is noted as a subcategory. This replaces the previous term "atypical glandular cells of undetermined significance (AGUS)." This term should not be confused with terminology for squamous cell abnormalities, which includes atypical squamous cells of undetermined significance (ASC-US). (See  <a class="medical medical_review" href="/z/d/html/3205.html" rel="external">"Cervical cancer screening: The cytology and human papillomavirus report", section on 'Intraepithelial cell abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atypical glandular cells, favor neoplastic</strong> – Endocervical is the only subcategory. This designation is for specimens that show features suggestive of, but not sufficient for, an interpretation of adenocarcinoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocervical adenocarcinoma in situ (AIS)</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenocarcinoma</strong> – Adenocarcinoma cells may be subcategorized as endocervical, endometrial, extrauterine, or NOS.</p><p></p><p class="headingAnchor" id="H19068430"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Glandular abnormalities are found in &lt;1 percent of cervical cytology samples, most commonly in patients ages ≥40 years (eg, 1.1 to 2.4/1000 at ages 40 to 69 versus 0 to 0.8/1000 in younger patients [<a href="#rid5">5</a>]) [<a href="#rid6">6-8</a>]. By contrast, abnormal squamous cytologic findings (atypical squamous cells or a squamous intraepithelial lesion) are more common and are more prevalent in patients ages 15 to 29 years [<a href="#rid5">5</a>].</p><p>There are few data regarding AGC during pregnancy or the postpartum period. Based upon available data, the incidence of AGC and of significant neoplasia appears to be similar or higher in pregnant compared with nonpregnant patients of similar age [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H2439938001"><span class="h1">ANATOMIC SITE OF ORIGIN OF AGC</span><span class="headingEndMark"> — </span>Almost all AGC originate from the endocervix or endometrium, but occasionally, further evaluation results in a diagnosis of disease at another site. Ovarian/fallopian tube cancer is the most common of these extrauterine sites and has been reported in 0.1 to 0.6 percent of patients with AGC [<a href="#rid7">7,11,12</a>]. More rarely, AGC is a sign of an occult glandular malignancy from a nongynecologic organ, such as the colon, breast, or stomach [<a href="#rid7">7,13-15</a>].</p><p>Endometrial polyps and tubal metaplasia are examples of benign uterine disorders that have been associated with AGC [<a href="#rid11">11,16</a>].</p><p class="headingAnchor" id="H16564920"><span class="h1">RISK OF PREMALIGNANT OR MALIGNANT DISEASE</span><span class="headingEndMark"> — </span>AGC on cervical cytology are associated with premalignant or malignant disease in approximately 30 percent of cases [<a href="#rid11">11,17-25</a>]. Interestingly, most of the lesions found upon histologic evaluation are squamous rather than glandular [<a href="#rid7">7,19</a>].</p><p class="headingAnchor" id="H483192"><span class="h2">Histologies in patients with AGC cytology</span><span class="headingEndMark"> — </span>Histologic evaluation of patients with AGC may identify normal findings or squamous or glandular lesions. The distribution of histology was illustrated in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Two literature reviews including approximately 4300 patients with AGC (or atypical glandular cells of undetermined significance [AGUS] for specimens evaluated using the pre-2001 Bethesda classification (see <a class="local">'Terminology'</a> above)) reported benign findings in 64 to 71 percent of cases [<a href="#rid7">7,19</a>]. Abnormalities included:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Squamous cervical intraepithelial neoplasia (CIN) – 20 to 28 percent, including:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Low-grade CIN (CIN 1) – 9 percent</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>High-grade CIN (CIN 2,3) – 11 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Squamous cervical carcinoma – 0.3 to 1.0 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cervical adenocarcinoma in situ (AIS) – 3 to 4 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cervical adenocarcinoma – 1 to 2 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endometrial hyperplasia – 1 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Endometrial adenocarcinoma – 2 to 3 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A Swedish national registry study included 14,625 patients with AGC on their first reported cervical cytology specimen who were followed for up to 15.5 years [<a href="#rid26">26</a>]. In this study, AGC was classified by the Swedish Association for Clinical Cytology, and subcategories of AGC were not used. On follow-up of the AGC cytology specimen within six months, the following histologies were noted:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Squamous cervical carcinoma – 0.3 percent</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cervical adenocarcinoma – 0.99 percent</p><p></p><p class="bulletIndent1">Patients with AGC continued to be at a higher risk of cervical cancer than patients with normal cytology for up to 15.5 years, with the highest risk within 3.5 years, and then decreasing over time. Compared with patients with normal index cytology, the risks were 24-fold at 0.5 to 3.5 years, 10-fold at 3.5 to 6.5 years, and 4.8-fold at 10.5 to 15.5 years. Patients with AGC were at a higher risk of adenocarcinoma than of squamous carcinoma. Interestingly, for up to 10.5 years, patients with AGC were at a higher risk of developing cervical cancer (either adenocarcinoma or squamous) than patients with high-grade squamous intraepithelial lesion, and the risk became comparable from 10.5 to 15.5 years. A limitation is that the study followed patients forward from an index cytology result but did not include information about subsequent cytology results. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective review of 238 patients with endometrial cancer, 50 (21 percent) had abnormal Pap smears, and 17 of the 50 abnormal results were AGC [<a href="#rid27">27</a>]. AGC correlated with cervical stromal invasion of the endometrial cancer.</p><p></p><p>The lower rate of glandular compared with squamous cervical abnormalities diagnosed in patients with AGC in literature reviews may be secondary to the lower sensitivity of cervical cytology for detecting endocervical glandular dysplasia and malignancy than for detecting squamous malignancy [<a href="#rid7">7,19</a>]. This lower sensitivity has been attributed to several factors: it can be difficult for the cytopathologist to distinguish between high-grade squamous cells and glandular cells; endometrial cells, reactive endocervical cells, tubal metaplasia, and cervical endometriosis may mimic AIS; and lesions may not be seen or sampled because they are small or high in the endocervical canal. Another reason for underdiagnosis is the presence of minimal, poorly preserved endocervical cells, which are difficult to assess [<a href="#rid28">28</a>].</p><p>AGC has also been associated with less frequent histologies, including adenosquamous cervical cancer and uterine carcinosarcoma (formerly referred to as malignant mixed müllerian tumors) [<a href="#rid29">29-31</a>].</p><p class="headingAnchor" id="H483365"><span class="h2">Correlation between AGC subcategory and subsequent histology</span><span class="headingEndMark"> — </span>The cytologic subcategory is somewhat predictive of the histologic diagnosis. As an example, in a study of 460 patients with AGC on cytology, the most common histology by subcategory was [<a href="#rid32">32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>AGC-not otherwise specified was associated with endometrial adenocarcinoma in 10.2 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AGC-endocervical (also abbreviated AEC) was associated with invasive cervical adenocarcinoma in 5.9 percent of cases, AIS in 2.4 percent of cases, and CIN 2,3 in 5.3 percent of cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AGC-endometrial was associated with endometrial adenocarcinoma in 27.8 percent of cases and atypical complex endometrial hyperplasia in 22.2 percent of cases.</p><p></p><p>A limitation of this study was that it combined AGC, favor neoplastic subcategories with other AGC categories (eg, AEC, favor neoplastic was combined with AEC), thus increasing the likelihood of malignancy in each subcategory.</p><p>There are few data about the histologic correlation of AGC classified as favor neoplastic. In one study (n = 138), high-grade CIN, AIS, or invasive cervical or endometrial cancer was found more often in patients with AGC, favor neoplastic compared with other patients with AGC (56 versus 8 percent) [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H6833383"><span class="h2">Frequency of a coexisting squamous cytologic abnormality</span><span class="headingEndMark"> — </span>Approximately one-half of patients with AGC have a coexisting squamous cytologic abnormality (atypical squamous cells or a squamous intraepithelial lesion), and these patients appear to be more likely to have a squamous rather than a glandular lesion [<a href="#rid19">19,32,33</a>]. As an example, in a study that included 353 patients with AGC who underwent histologic evaluation, the proportion of squamous histologic lesions was higher in those with AGC plus a squamous cytologic finding (squamous histology: 90 percent; glandular histology: 10 percent) compared with AGC cytology alone (squamous histology: 72 percent; glandular histology: 28 percent) [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H1343352259"><span class="h1">RISK FACTORS FOR MALIGNANT OR PREMALIGNANT DISEASE</span></p><p class="headingAnchor" id="H8318502"><span class="h2">Human papillomavirus infection</span><span class="headingEndMark"> — </span>For patients with AGC, testing for high-risk human papillomavirus (HPV) is not as reliable for triaging follow-up as it is for atypical squamous cells because AGC may also represent upper tract pathology (see <a class="local">'Anatomic site of origin of AGC'</a> above) [<a href="#rid33">33,34</a>]. However, it is still used in the evaluation of patients with AGC and a positive high-risk HPV test is associated with an increased risk for a subsequent histologic diagnosis of cervical intraepithelial neoplasia (CIN) [<a href="#rid35">35-39</a>]. (See <a class="local">'Follow-up of patients with negative or low-grade histologic findings on initial evaluation (colposcopy and biopsy)'</a> below.)</p><p>In a cohort study of over 1.5 million patients followed for more than a decade, the immediate risk of CIN 3+ in patients with AGC (all categories) on cytology and an unknown PAP/HPV history (3252 total patients) was increased in those who were HPV-positive compared with those who were HPV-negative (26 versus 1 percent) [<a href="#rid40">40</a>]. The five-year risk of developing CIN 3+ in this cohort was 35 and 1.5 percent, respectively. In another study in which 222 patients had HPV-positive AGC, subsequent evaluation revealed 93 cases of high-grade squamous intraepithelial lesion (HSIL), 33 cases of cervical adenocarcinoma in situ, and 6 cases of invasive cervical adenocarcinoma, whereas among the 170 HPV-negative patients with AGC, there were 4 cases of HSIL, 1 case of invasive cervical squamous cell cancer, 5 cases of endometrial cancer, and 1 case of breast cancer [<a href="#rid39">39</a>].</p><p>HPV genotyping can also help stratify risk. In a cohort study of 341 patients with non-16/18 HPV-positive AGC, those with HPV 33 and 31 had higher rates of CIN 3 or greater than patients with HPV 45 or 52 (82.9, 82.1, 49, and 42.5, respectively) [<a href="#rid41">41</a>]. If a patient is HPV positive or negative, when co-tested with cytology, the diagnostic work-up and management are similar [<a href="#rid42">42</a>]. The use of other markers (ie, Dual Stain cytology with p16/Ki-67) for triage of squamous lesions has not been studied in patients with AGC [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/3219.html" rel="external">"Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing", section on 'Sample processing'</a>.)</p><p class="headingAnchor" id="H8318382"><span class="h2">Older age</span><span class="headingEndMark"> — </span>The risk of malignancy in patients with AGC increases with age [<a href="#rid11">11,17,22,32,44</a>]. In one retrospective study of 662 patients with AGC, the overall rate of malignancy was highest in patients ≥50 years (15 percent) compared with those ages 40 to 49 years (2.8 percent) or &lt;40 years (2.0 percent) [<a href="#rid11">11</a>]. In patients ≥50 years, endometrial malignancy was most common, whereas in patients &lt;40 years, cervical malignancy was most common.</p><p class="headingAnchor" id="H483388"><span class="h2">Persistent AGC-NOS</span><span class="headingEndMark"> — </span>Patients with persistent AGC-NOS on two or more cytology results are at especially high risk of significant glandular disease [<a href="#rid17">17</a>]. In one study, three of five postmenopausal patients with persistence on repeated cytologic testing were subsequently found to have endometrial adenocarcinoma [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3"><span class="h1">INITIAL EVALUATION</span></p><p class="headingAnchor" id="H905266612"><span class="h2">General principles</span></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of AGC on cervical cytology is a significant marker for premalignant disease of the cervix or endometrium; thus, evaluation includes testing of both sites. The approach to initial evaluation differs somewhat by AGC subcategory and pregnancy status. (See <a class="local">'All AGC categories (except endometrial)'</a> below and <a class="local">'AGC-endometrial'</a> below and <a class="local">'Modifications for pregnant patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of patients with negative or low-grade histologic findings (no cervical intraepithelial neoplasia [CIN] 2 or higher [CIN 2+], no adenocarcinoma in situ [AIS], and no cancer on colposcopy with directed cervical biopsies and sampling of the endocervical canal) is described below. (See <a class="local">'Follow-up of patients with negative or low-grade histologic findings on initial evaluation (colposcopy and biopsy)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of patients with positive findings depends on the histologic diagnosis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3244.html" rel="external">"Invasive cervical cancer: Staging and evaluation of lymph nodes"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3218.html" rel="external">"Cervical adenocarcinoma in situ"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/13930.html" rel="external">"Small cell neuroendocrine carcinoma of the cervix"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3217.html" rel="external">"Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3251.html" rel="external">"Endometrial carcinoma: Staging and surgical treatment"</a>.)</p><p></p><p>Procedures for colposcopy and endometrial sampling are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3260.html" rel="external">"Colposcopy"</a> and  <a class="medical medical_review" href="/z/d/html/3254.html" rel="external">"Endometrial sampling procedures"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">All AGC categories (except endometrial)</span><span class="headingEndMark"> — </span>Nonpregnant patients with cervical cytology of AGC-not otherwise specified or AGC-endocervical (including those classified as favor neoplastic), AIS, or adenocarcinoma are evaluated initially with the following  (<a class="graphic graphic_algorithm graphicRef127899" href="/z/d/graphic/127899.html" rel="external">algorithm 1</a>) [<a href="#rid45">45-47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Colposcopy and sampling of the endocervical canal (endocervical curettage).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endometrial sampling is performed for patients ≥35 years old and for patients &lt;35 years old at risk for endometrial neoplasia (risk factors or symptoms are present)  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">table 3</a>). It is important to get an adequate endometrial sample.</p><p></p><p>This evaluation is required regardless of human papillomavirus (HPV) results. </p><p class="headingAnchor" id="H5"><span class="h2">AGC-endometrial</span><span class="headingEndMark"> — </span>Nonpregnant patients who have AGC-endometrial should be evaluated with endometrial sampling and endocervical sampling; colposcopy is not required but may be performed as part of the initial evaluation  (<a class="graphic graphic_algorithm graphicRef127899" href="/z/d/graphic/127899.html" rel="external">algorithm 1</a>) [<a href="#rid45">45,47</a>]. Patients are then treated, as appropriate, for the histologic abnormality that is detected.</p><p>If the cytology report also has abnormal squamous findings (atypical squamous cells or squamous intraepithelial lesion) in combination with AGC-endometrial, colposcopy should be performed. (See  <a class="medical medical_review" href="/z/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening"</a>.)</p><p class="headingAnchor" id="H4097191389"><span class="h2">Modifications for pregnant patients</span><span class="headingEndMark"> — </span>For pregnant patients with AGC, endocervical sampling with a curette and endometrial sampling should <strong>not</strong> be performed as there is a risk of disturbing the pregnancy; however, the endocervical canal may be sampled gently with a cytobrush. Colposcopic examination may also be performed approximately six weeks later; endocervical lesions initially missed in early pregnancy may be seen as the pregnancy progresses and eversion of the endocervix occurs [<a href="#rid48">48,49</a>].</p><p class="headingAnchor" id="H10"><span class="h1">FOLLOW-UP OF PATIENTS WITH NEGATIVE OR LOW-GRADE HISTOLOGIC FINDINGS ON INITIAL EVALUATION (COLPOSCOPY AND BIOPSY)</span><span class="headingEndMark"> — </span>The follow-up of patients with negative or low-grade (cervical intraepithelial neoplasia [CIN] 1) histologic findings on initial evaluation depends upon the AGC subcategory. Some patients will require cervical conization because glandular neoplasia of the cervix, in contrast to squamous disease, is often characterized by noncontiguous lesions ("skip lesions") and some glandular disease may be located high in the cervical canal.</p><p class="headingAnchor" id="H11"><span class="h2">AGC-NOS or AEC-NOS cytology</span><span class="headingEndMark"> — </span>The initial approach to AGC-not otherwise specified (AGC-NOS) or atypical endocervical cells (AEC)-NOS cytology is as follows  (<a class="graphic graphic_algorithm graphicRef127900" href="/z/d/graphic/127900.html" rel="external">algorithm 2</a>) [<a href="#rid45">45,47</a>]:</p><p>If the initial evaluation (colposcopy and biopsies) is CIN 2 or less (no CIN 2+, adenocarcinoma in situ [AIS], or cancer is found), then co-testing with cervical cytology and human papillomavirus (HPV) testing at one and two years is performed:</p><p class="bulletIndent1"><span class="glyph">●</span>If cytology and HPV testing are both negative – Repeat co-testing in three years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If any abnormality is found at one or two years – Perform colposcopy with endocervical curettage (ECC) and then endometrial sampling if the colposcopic findings are nondiagnostic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If CIN 2 or CIN 3, but no glandular abnormalities are identified, management is directed by the specific abnormality. (See  <a class="medical medical_review" href="/z/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If colposcopy with ECC and endometrial sampling are nondiagnostic, we suggest conization (cold knife, electrocautery, or laser techniques are acceptable). In addition, vaginal colposcopy should be performed in patients with a history of exposure to diethylstilbestrol. </p><p></p><p>If the initial evaluation (colposcopy and biopsies) is positive for CIN 2+ but no glandular neoplasia is found, management is directed by the specific abnormality. (See  <a class="medical medical_review" href="/z/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a>.)</p><p class="headingAnchor" id="H481210"><span class="h2">AGC, favor neoplastic; adenocarcinoma in situ; or adenocarcinoma cytology</span><span class="headingEndMark"> — </span>Cervical cytology classified as AGC, favor neoplastic; AIS; or adenocarcinoma is associated with a very high risk of underlying invasive disease [<a href="#rid23">23</a>]. If the initial evaluation (colposcopy and biopsy) is negative for AIS or cancer, the following is our approach:</p><p class="bulletIndent1"><span class="glyph">●</span>A diagnostic excisional procedure followed by an ECC of the remaining endocervix is required  (<a class="graphic graphic_algorithm graphicRef127900" href="/z/d/graphic/127900.html" rel="external">algorithm 2</a>) [<a href="#rid45">45,47</a>]. We suggest a cold knife conization rather than a loop electrosurgical excision procedure to avoid thermal artifact at the margins. (See  <a class="medical medical_review" href="/z/d/html/3255.html" rel="external">"Cervical intraepithelial neoplasia: Diagnostic excisional procedures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the results of the diagnostic excisional procedure are negative, endometrial sampling is required. Due to skip lesions and the higher incidence of lower uterine segment involvement, we perform a dilation and curettage at the same time as the cone biopsy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the results of endometrial sampling are negative, a pelvic ultrasound and other testing (eg, cancer antigen 125 [CA 125]) can be performed to look for a fallopian tube or ovarian lesion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If pelvic ultrasound and CA 125 are also negative, we obtain cervical cytology, HPV, and ECC every six months. (See <a class="local">'Patients with persistent AGC and negative colposcopy, endometrial biopsy, and conization'</a> below.)</p><p></p><p>Positive findings are managed as appropriate for the abnormality identified. </p><p class="headingAnchor" id="H481535"><span class="h2">AGC-endometrial cytology</span><span class="headingEndMark"> — </span>If the initial evaluation (endometrial and endocervical sampling) is negative, then  (<a class="graphic graphic_algorithm graphicRef127899" href="/z/d/graphic/127899.html" rel="external">algorithm 1</a>) [<a href="#rid45">45,47</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Colposcopy is performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If colposcopy is negative, we repeat endometrial and endocervical sampling and pelvic ultrasound (to assess the uterine lining) within six months. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If clinical concern for malignancy is high, our authors have also used pelvic ultrasound and hysteroscopy with dilation and curettage in this setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If repeat endometrial and endocervical sampling are negative, the patient may resume routine screening for cervical cancer. (See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p></p><p>Positive findings are managed as appropriate for the abnormality identified. </p><p class="headingAnchor" id="H481607"><span class="h1">PATIENTS WITH PERSISTENT AGC AND NEGATIVE COLPOSCOPY, ENDOMETRIAL BIOPSY, AND CONIZATION</span><span class="headingEndMark"> — </span>Patients with persistent cytologic findings associated with a high risk of malignancy (persistent AGC-not otherwise specified; AGC-endocervical; AGC-endometrial; AGC, favor neoplastic; adenocarcinoma in situ; adenocarcinoma) and who have negative cervical and endometrial findings despite comprehensive evaluation (ie, colposcopy, endometrial biopsy, conization) should be evaluated for primary or metastatic disease involving the ovary/fallopian tube. Occasionally, AGC is a sign of an occult glandular malignancy from the ovary/fallopian tube or a nongynecologic organ, such as the colon, breast, or stomach [<a href="#rid7">7,13-15</a>]. AGC with a negative human papillomavirus (HPV) test is rare but can be consistent with AGC of noncervical origin. This result does not exclude a uterine or cervical origin of AGC. </p><p>The first-line study is a transvaginal ultrasound and cancer antigen 125 (CA 125). Patients with an adnexal mass or an elevated tumor marker should undergo further evaluation for ovarian or fallopian tube cancer. (See  <a class="medical medical_review" href="/z/d/html/83704.html" rel="external">"Approach to the patient with an adnexal mass"</a> and  <a class="medical medical_review" href="/z/d/html/7563.html" rel="external">"Screening for ovarian cancer", section on 'Lack of benefit of screening strategies'</a>.)</p><p>If the above evaluation is negative, the clinician should confirm that age-appropriate breast and colon cancer screening has been performed and order this screening if it has not been performed. Rarely, these patients have a primary tumor at an occult site, particularly the breast or colon. </p><p>There is no standard work-up for patients with persistent AGC that is unexplained. Further evaluation, which may include abdominal and pelvic imaging and serum tumor markers, depends on the medical history and physical examination and physician and patient preferences. In a systematic review that included almost 7000 patients with AGC, 203 malignancies were diagnosed after histologic follow-up and included endometrial cancer (57.6 percent), cervical adenocarcinoma (23.6 percent), cervical squamous carcinoma (5.4 percent), ovarian or fallopian tube carcinoma (6.4 percent), and other malignancy (6.9 percent, histologic types not provided) [<a href="#rid7">7</a>]. </p><p class="headingAnchor" id="H2333563426"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117738.html" rel="external">"Society guideline links: Cervical cancer screening, prevention, and management"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/8412.html" rel="external">"Patient education: Cervical cancer screening (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> <strong>and risk of malignancy </strong>– Atypical glandular cells (AGC) are found in &lt;1 percent of cervical cytology samples. AGC are associated with premalignant or malignant lesions of the endocervix or endometrium in approximately 30 percent of cases. Most of the lesions found upon histologic evaluation are squamous rather than glandular. (See <a class="local">'Incidence'</a> above and <a class="local">'Risk of premalignant or malignant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Site of origin</strong> – Almost all AGC originate from the endocervix or endometrium, but occasionally, AGC have been associated with ovarian/fallopian tube malignancy or vaginal cancer and, even less commonly, with an occult glandular malignancy from a nongynecologic organ, such as the colon, breast, or stomach. Endometrial polyps and tubal metaplasia are examples of benign uterine disorders that have been associated with AGC. (See <a class="local">'Anatomic site of origin of AGC'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for malignancy</strong> – In patients with AGC, older age (eg, ≥50 years) is a risk factor for malignancy. Testing for high-risk human papillomavirus (HPV), however, is not as reliable for triaging follow-up as it is for atypical squamous cells because AGC may also represent upper tract pathology. (See <a class="local">'Risk factors for malignant or premalignant disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonpregnant patients with AGC-not otherwise specified (AGC-NOS) or AGC-endocervical (AEC; including those classified as favor neoplastic), adenocarcinoma in situ (AIS), or adenocarcinoma are evaluated initially with cervical colposcopy plus directed cervical biopsies and sampling of the endocervical canal  (<a class="graphic graphic_algorithm graphicRef127899" href="/z/d/graphic/127899.html" rel="external">algorithm 1</a>). Endometrial sampling is performed for patients ≥35 years old and for younger patients at risk for endometrial neoplasia (risk factors or symptoms are present)  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">table 3</a>). This evaluation is required regardless of HPV results. (See <a class="local">'All AGC categories (except endometrial)'</a> above.):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonpregnant patients with AGC-endometrial are evaluated with endometrial sampling and endocervical sampling; colposcopy is not required but may also be performed as part of the initial evaluation  (<a class="graphic graphic_algorithm graphicRef127899" href="/z/d/graphic/127899.html" rel="external">algorithm 1</a>). Patients are treated, as appropriate, for the histologic abnormality that is detected. If the cytology report also has abnormal squamous findings (atypical squamous cells or squamous intraepithelial lesion) in combination with AGC-endometrial, colposcopy should be performed. (See <a class="local">'AGC-endometrial'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For pregnant patients with AGC, endocervical sampling with a curette and endometrial sampling should <strong>not</strong> be performed as there is a risk of disturbing the pregnancy; however, the endocervical canal may be sampled gently with a cytobrush or evaluated with colposcopic examination six weeks later. (See <a class="local">'Modifications for pregnant patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with negative or low-grade findings on initial evaluation of AGC-NOS; AGC, favor neoplastic; AIS; or adenocarcinoma require further assessment, which depends upon the AGC subcategory  (<a class="graphic graphic_algorithm graphicRef127900" href="/z/d/graphic/127900.html" rel="external">algorithm 2</a>). (See <a class="local">'Follow-up of patients with negative or low-grade histologic findings on initial evaluation (colposcopy and biopsy)'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with negative or low-grade findings on initial evaluation of AGC-endometrial should have colposcopy, and if negative, endometrial and endocervical sampling as well as pelvic ultrasound are repeated within six months. If colposcopy and repeat endometrial and endocervical sampling are negative, the patient may resume routine screening for cervical cancer. (See <a class="local">'AGC-endometrial cytology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent findings</strong> – Patients with persistent cytologic findings associated with a high risk of malignancy who have negative cervical and endometrial findings despite comprehensive evaluation (ie, colposcopy, endometrial biopsy, conization) should be evaluated for primary or metastatic disease involving the ovary/fallopian tube. The first-line study is a transvaginal ultrasound and cancer antigen 125 (CA 125). Patients with an adnexal mass or an elevated tumor marker are further evaluated for ovarian or fallopian tube cancer. </p><p></p><p class="bulletIndent1">If this evaluation is negative, the clinician should confirm that age-appropriate breast and colon cancer screening has been performed and order this screening if it has not been performed. Rarely, these patients have a primary tumor at an occult site, particularly the breast or colon. (See <a class="local">'Patients with persistent AGC and negative colposcopy, endometrial biopsy, and conization'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 1989; 262:931.</a></li><li><a class="nounderline abstract_t">Broder S. From the National Institutes of Health. JAMA 1992; 267:1892.</a></li><li><a class="nounderline abstract_t">Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.</a></li><li><a class="nounderline abstract_t">Nayar R, Wilbur DC. The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)". J Low Genit Tract Dis 2015; 19:175.</a></li><li><a class="nounderline abstract_t">Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004; 191:105.</a></li><li><a class="nounderline abstract_t">Marques JP, Costa LB, Pinto AP, et al. Atypical glandular cells and cervical cancer: systematic review. Rev Assoc Med Bras (1992) 2011; 57:234.</a></li><li><a class="nounderline abstract_t">Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107:701.</a></li><li><a class="nounderline abstract_t">Harbhajanka A, Dahoud W, Michael CW. Can we predict histological outcome of distinctive cohorts of patients with glandular cell abnormalities on ThinPrep Papanicolaou testing based on human papillomavirus status, age, and associated squamous abnormalities? Diagn Cytopathol 2019; 47:1028.</a></li><li><a class="nounderline abstract_t">Tam KF, Cheung AN, Szeto E, Ngan HY. Atypical glandular cells diagnosed during pregnancy and the postpartum period: a retrospective analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155:213.</a></li><li><a class="nounderline abstract_t">Chhieng DC, Elgert P, Cangiarella JF, Cohen JM. Significance of AGUS Pap smears in pregnant and postpartum women. Acta Cytol 2001; 45:294.</a></li><li><a class="nounderline abstract_t">Zhao C, Florea A, Onisko A, Austin RM. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol 2009; 114:383.</a></li><li><a class="nounderline abstract_t">Cheng WF, Chen YL, You SL, et al. Risk of gynaecological malignancies in cytologically atypical glandular cells: follow-up study of a nationwide screening population. BJOG 2011; 118:34.</a></li><li><a class="nounderline abstract_t">Boyraz G, Basaran D, Salman MC, et al. Histological Follow-Up in Patients with Atypical Glandular Cells on Pap Smears. J Cytol 2017; 34:203.</a></li><li><a class="nounderline abstract_t">Schnatz PF, Pattison K, Mandavilli S, et al. Atypical glandular cells on cervical cytology and breast disease: what is the association? J Low Genit Tract Dis 2011; 15:189.</a></li><li><a class="nounderline abstract_t">Kim MK, Lee YK, Hong SR, Lim KT. Clinicopathological significance of atypical glandular cells on cervicovaginal Pap smears. Diagn Cytopathol 2017; 45:867.</a></li><li><a class="nounderline abstract_t">Saad RS, Takei H, Liu YL, et al. Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears. Acta Cytol 2006; 50:48.</a></li><li><a class="nounderline abstract_t">Sharpless KE, Schnatz PF, Mandavilli S, et al. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol 2005; 105:494.</a></li><li><a class="nounderline abstract_t">Veljovich DS, Stoler MH, Andersen WA, et al. Atypical glandular cells of undetermined significance: a five-year retrospective histopathologic study. Am J Obstet Gynecol 1998; 179:382.</a></li><li><a class="nounderline abstract_t">Geier CS, Wilson M, Creasman W. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol 2001; 184:64.</a></li><li><a class="nounderline abstract_t">Eddy GL, Strumpf KB, Wojtowycz MA, et al. Biopsy findings in five hundred thirty-one patients with atypical glandular cells of uncertain significance as defined by the Bethesda system. Am J Obstet Gynecol 1997; 177:1188.</a></li><li><a class="nounderline abstract_t">Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 2001; 93:1.</a></li><li><a class="nounderline abstract_t">DeSimone CP, Day ME, Tovar MM, et al. Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol 2006; 107:1285.</a></li><li><a class="nounderline abstract_t">Tam KF, Cheung AN, Liu KL, et al. A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification. Gynecol Oncol 2003; 91:603.</a></li><li><a class="nounderline abstract_t">Scheiden R, Wagener C, Knolle U, et al. Atypical glandular cells in conventional cervical smears: incidence and follow-up. BMC Cancer 2004; 4:37.</a></li><li><a class="nounderline abstract_t">Hammoud MM, Haefner HK, Michael CW, Ansbacher R. Atypical glandular cells of undetermined significance. Histologic findings and proposed management. J Reprod Med 2002; 47:266.</a></li><li><a class="nounderline abstract_t">Wang J, Andrae B, Sundström K, et al. Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study. BMJ 2016; 352:i276.</a></li><li><a class="nounderline abstract_t">Khumthong K, Aue-Aungkul A, Kleebkaow P, et al. Association of Abnormal Pap Smear with Occult Cervical Stromal Invasion in Patients with Endometrial Cancer. Asian Pac J Cancer Prev 2019; 20:2847.</a></li><li><a class="nounderline abstract_t">Ruba S, Schoolland M, Allpress S, Sterrett G. Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears. Cancer 2004; 102:280.</a></li><li><a class="nounderline abstract_t">Kim TJ, Kim HS, Park CT, et al. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears. Gynecol Oncol 1999; 73:292.</a></li><li><a class="nounderline abstract_t">Zhao C, Florea A, Austin RM. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med 2010; 134:103.</a></li><li><a class="nounderline abstract_t">Cheng RF, Hernandez E, Anderson LL, et al. Clinical significance of a cytologic diagnosis of atypical glandular cells of undetermined significance. J Reprod Med 1999; 44:922.</a></li><li><a class="nounderline abstract_t">Zhao C, Austin RM, Pan J, et al. Clinical significance of atypical glandular cells in conventional pap smears in a large, high-risk U.S. west coast minority population. Acta Cytol 2009; 53:153.</a></li><li><a class="nounderline abstract_t">Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287:2120.</a></li><li><a class="nounderline abstract_t">Jiang X, Anderson C, Sharpless KE, et al. Atypical Glandular Cells of Endometrial Origin and the Risk of Endometrial Cancer. J Low Genit Tract Dis 2015; 19:194.</a></li><li><a class="nounderline abstract_t">Derchain SF, Rabelo-Santos SH, Sarian LO, et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol 2004; 95:618.</a></li><li><a class="nounderline abstract_t">Castle PE, Fetterman B, Poitras N, et al. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010; 115:243.</a></li><li><a class="nounderline abstract_t">Irvin W, Evans SR, Andersen W, et al. The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol 2005; 193:559.</a></li><li><a class="nounderline abstract_t">Zeferino LC, Rabelo-Santos SH, Villa LL, et al. Value of HPV-DNA test in women with cytological diagnosis of atypical glandular cells (AGC). Eur J Obstet Gynecol Reprod Biol 2011; 159:160.</a></li><li><a class="nounderline abstract_t">Norman I, Hjerpe A, Dillner J. Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study. BMJ Open 2017; 7:e017070.</a></li><li><a class="nounderline abstract_t">Egemen D, Cheung LC, Chen X, et al. Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020; 24:132.</a></li><li><a class="nounderline abstract_t">Yilmaz E, Lagheden C, Ghaderi M, et al. Assessment of Human Papillomavirus Non-16/18, Type-Specific Risk for Cervical Intraepithelial Neoplasia Grade 3 or Worse Among Women With Cervical Atypical Glandular Cells. Obstet Gynecol 2023; 142:679.</a></li><li><a class="nounderline abstract_t">Verdoodt F, Jiang X, Williams M, et al. High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis. Int J Cancer 2016; 138:303.</a></li><li><a class="nounderline abstract_t">Chen CC, Huang LW, Bai CH, Lee CC. Predictive value of p16/Ki-67 immunocytochemistry for triage of women with abnormal Papanicolaou test in cervical cancer screening: a systematic review and meta-analysis. Ann Saudi Med 2016; 36:245.</a></li><li><a class="nounderline abstract_t">Koonings PP, Price JH. Evaluation of atypical glandular cells of undetermined significance: is age important? Am J Obstet Gynecol 2001; 184:1457.</a></li><li><a class="nounderline abstract_t">Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020; 24:102.</a></li><li><a class="nounderline abstract_t">Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am J Obstet Gynecol 2016; 214:689.e1.</a></li><li class="breakAll">https://www.asccp.org/guidelines.</li><li><a class="nounderline abstract_t">House M, McCabe R, Socrate S. Using imaging-based, three-dimensional models of the cervix and uterus for studies of cervical changes during pregnancy. Clin Anat 2013; 26:97.</a></li><li><a class="nounderline abstract_t">Rechberger T, Uldbjerg N, Oxlund H. Connective tissue changes in the cervix during normal pregnancy and pregnancy complicated by cervical incompetence. Obstet Gynecol 1988; 71:563.</a></li></ol></div><div id="topicVersionRevision">Topic 3229 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2754794" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548812" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : From the National Institutes of Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966386" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The 2001 Bethesda System: terminology for reporting results of cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25943863" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295350" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diagnoses and outcomes in cervical cancer screening: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21537713" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Atypical glandular cells and cervical cancer: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507944" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical significance of atypical glandular cells on cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31359607" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Can we predict histological outcome of distinctive cohorts of patients with glandular cell abnormalities on ThinPrep Papanicolaou testing based on human papillomavirus status, age, and associated squamous abnormalities?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21227567" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Atypical glandular cells diagnosed during pregnancy and the postpartum period: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11393057" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Significance of AGUS Pap smears in pregnant and postpartum women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19501894" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21054764" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk of gynaecological malignancies in cytologically atypical glandular cells: follow-up study of a nationwide screening population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29118475" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Histological Follow-Up in Patients with Atypical Glandular Cells on Pap Smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436728" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Atypical glandular cells on cervical cytology and breast disease: what is the association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28771986" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinicopathological significance of atypical glandular cells on cervicovaginal Pap smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16514840" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738014" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dysplasia associated with atypical glandular cells on cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731842" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Atypical glandular cells of undetermined significance: a five-year retrospective histopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174481" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical evaluation of atypical glandular cells of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396918" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Biopsy findings in five hundred thirty-one patients with atypical glandular cells of uncertain significance as defined by the Bethesda system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241259" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16738153" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14675684" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15257755" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Atypical glandular cells in conventional cervical smears: incidence and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12012877" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Atypical glandular cells of undetermined significance. Histologic findings and proposed management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26869597" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31554386" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Association of Abnormal Pap Smear with Occult Cervical Stromal Invasion in Patients with Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15376198" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10329049" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20073612" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589401" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical significance of a cytologic diagnosis of atypical glandular cells of undetermined significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365967" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical significance of atypical glandular cells in conventional pap smears in a large, high-risk U.S. west coast minority population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966387" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25856122" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Atypical Glandular Cells of Endometrial Origin and the Risk of Endometrial Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15581973" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093895" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098895" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The utility of HPV DNA triage in the management of cytological AGC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21680079" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Value of HPV-DNA test in women with cytological diagnosis of atypical glandular cells (AGC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29247086" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243308" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37535949" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Assessment of Human Papillomavirus Non-16/18, Type-Specific Risk for Cervical Intraepithelial Neoplasia Grade 3 or Worse Among Women With Cervical Atypical Glandular Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583258" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27478909" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Predictive value of p16/Ki-67 immunocytochemistry for triage of women with abnormal Papanicolaou test in cervical cancer screening: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11408868" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Evaluation of atypical glandular cells of undetermined significance: is age important?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243307" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26829507" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26829507" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23168534" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Using imaging-based, three-dimensional models of the cervix and uterus for studies of cervical changes during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3353047" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Connective tissue changes in the cervix during normal pregnancy and pregnancy complicated by cervical incompetence.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
